Cannabidiol
Best for
Reduce everyday pain intensity
Likely strong benefit · 45–600 mg/day for 1–9 weeks · 1 meta-analysis , n=378
12 papers · 11 claims · 47 outcomes scored · 7 positive
Outcomes
What cannabidiol actually does, by outcome
Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.
Lower intensity, fewer flares, and longer stretches of relief.
Fewer episodes and steadier brain electrical activity day and night.
The background hum of worry that colors everything gets quieter.
Quiets the health worries and body tension that build with age.
Quiets the overthinking that hijacks execution right before you compete.
Everyday pressure stops running your nervous system hot.
Good days come more often and bad ones feel less heavy.
Deeper, less interrupted nights that leave you recharged by morning.
Lowers the weight of sadness, low energy, and emotional numbness over weeks.
Compensates for the sunlight deficit when days get short.
| Outcome | Effect | Evidence | Dose | Weeks | Rank |
|---|---|---|---|---|---|
| Reduce everyday pain intensity Likely strong benefit | | 6 meta-analyses n=378 Meta-analyzed | 45–600 mg | 1–9 wk | #6/55 |
| Reduce seizure frequency in epilepsy Likely modest benefit | | 1 RCT n=149 | 50 mg/kg/day | 16 wk | — |
| Lower day-to-day anxiety Not enough research | | 4 meta-analyses n=129 Meta-analyzed | 50–600 mg | 4 wk | — |
| Ease anxiety in older adults Not enough research | | 4 meta-analyses n=129 Meta-analyzed | 50–600 mg | 4 wk | — |
| Reduce pre-competition anxiety Not enough research | | 4 meta-analyses n=129 Meta-analyzed | 50–600 mg | 4 wk | — |
| Reduce daily stress Not enough research | | 2 RCTs n=48 | 50–600 mg | 4 wk | — |
| Lift and steady your mood Not enough research | | 1 RCT n=48 | 600 mg | — | #6/20 |
| Improve overall sleep quality Not enough research | | 3 RCTs n=43 | 45–300 mg | 8–9 wk | — |
| Ease depression symptoms Not enough research | | 2 RCTs n=43 | 45–600 mg | 4–9 wk | — |
| Ease winter depression symptoms Not enough research | | 2 RCTs n=43 | 45–600 mg | 4–9 wk | — |
| Ease depression tied to chronic pain Not enough research | | 2 RCTs n=43 | 45–600 mg | 4–9 wk | — |
Recommended Cannabidiol products
Real products that dose Cannabidiol where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.
-
LuZa Basic
Full Spectrum CBD 250 mg
Well dosed 250 mg/day A formula -
CBDistillery
Relief + Relax CBD Softgels 30 mg
Well dosed 100 mg/day A formula -
OXZGEN
Hemp Derived CBD Tincture 1500 mg
Well dosed 50 mg/day A formula -
CBDistillery ahhh distilled
CBD Softgels 30 mg Full Spectrum
Well dosed 100 mg/day A formula -
CBDPure
CBD Softgels 750
Well dosed 0.5 Gram(s)/day A formula -
CBDistillery ahhh distilled
CBD Softgels Broad Spectrum 30 mg
Well dosed 76 mg/day A formula
Chosen for adequate Cannabidiol dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.
Sources
- 1. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD). (2019) ↑
- 2. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. (2020) ↑
- 3. The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. (2022) ↑
- 4. Indications of Cannabinoids for the Palliation of Cancer-Associated Symptoms: A Systematic Review and Meta-Analysis. (2025) ↑
- 5. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. (2023) ↑
- 6. The Acute Effects of Cannabidiol on Physiological and Subjective Responses to Endurance Exercise: A Dose-Ranging Randomised Controlled Crossover Trial. (2025) ↑
- 7. Effects and safety of a CBD-rich Cannabis sativa oil in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial - CANOA - cannabis for osteoarthritis. (2025) ↑
- 8. A preliminary randomized trial of the safety, tolerability, and clinical effects of hemp-derived cannabidiol in alcohol use disorder. (2025) ↑
- 9. Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. (2026) ↑
- 10. Effects of Oral Cannabidiol on Health and Fitness in Healthy Adults: An 8-Week Randomized Trial. (2023) ↑
Generated August 14, 2026
Related
More evidence for Cannabidiol
Evidence map
Stress
NewStress: evidence map across 46 supplements
Evidence coverage map
Jul 30, 2026
Evidence map
Sleep
NewSleep: evidence map across 37 supplements
Evidence coverage map
Jul 30, 2026
Ingredient evidence
Ingredient evidence
New5-HTP
All scored outcomes
Aug 14, 2026
Ingredient evidence
Ingredient evidence
NewAshwagandha
All scored outcomes
Aug 14, 2026
Ingredient evidence
Ingredient evidence
NewBergamot (Citrus bergamia)
All scored outcomes
Aug 14, 2026
Ingredient evidence
Ingredient evidence
NewCaffeine
All scored outcomes
Aug 14, 2026